In CAR-NK cell line studies, Her2 (expressed on a subset of breast cancer cells) is the most used target for solid tumors, while the CD19 antigen (B cell malignancies) is the most popular in hematological cancers (Fig. 1b). Here, ERBB2 is linked to breast carcinoma.